Syros Pharmaceuticals Statistics
Share Statistics
Syros Pharmaceuticals has 26.83M shares outstanding. The number of shares has increased by 1.43% in one year.
| Shares Outstanding | 26.83M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.08% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 17.43M |
| Failed to Deliver (FTD) Shares | 24.99K |
| FTD / Avg. Volume | 0.27% |
Short Selling Information
The latest short interest is 1.57M, so 5.83% of the outstanding shares have been sold short.
| Short Interest | 1.57M |
| Short % of Shares Out | 5.83% |
| Short % of Float | 8.98% |
| Short Ratio (days to cover) | 0.07 |
Valuation Ratios
The PE ratio is -1.34 and the forward PE ratio is -0.14.
| PE Ratio | -1.34 |
| Forward PE | -0.14 |
| PS Ratio | 22.21 |
| Forward PS | 0.2 |
| PB Ratio | 13.24 |
| P/FCF Ratio | -2.01 |
| PEG Ratio | n/a |
Enterprise Valuation
Syros Pharmaceuticals Inc. has an Enterprise Value (EV) of 143.21M.
| EV / Earnings | -0.87 |
| EV / Sales | 14.41 |
| EV / EBITDA | -0.91 |
| EV / EBIT | -1.11 |
| EV / FCF | -1.3 |
Financial Position
The company has a current ratio of 3.95, with a Debt / Equity ratio of 2.47.
| Current Ratio | 3.95 |
| Quick Ratio | 3.95 |
| Debt / Equity | 2.47 |
| Total Debt / Capitalization | 71.22 |
| Cash Flow / Debt | -2.66 |
| Interest Coverage | -25.16 |
Financial Efficiency
Return on equity (ROE) is -9.88% and return on capital (ROIC) is -163.82%.
| Return on Equity (ROE) | -9.88% |
| Return on Assets (ROA) | -0.98% |
| Return on Capital (ROIC) | -163.82% |
| Revenue Per Employee | 146.12K |
| Profits Per Employee | -2.42M |
| Employee Count | 68 |
| Asset Turnover | 0.06 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -96.5% in the last 52 weeks. The beta is 1.59, so Syros Pharmaceuticals 's price volatility has been higher than the market average.
| Beta | 1.59 |
| 52-Week Price Change | -96.5% |
| 50-Day Moving Average | 0.91 |
| 200-Day Moving Average | 3.4 |
| Relative Strength Index (RSI) | 35.15 |
| Average Volume (20 Days) | 9.21M |
Income Statement
In the last 12 months, Syros Pharmaceuticals had revenue of 9.94M and earned -164.57M in profits. Earnings per share was -5.81.
| Revenue | 9.94M |
| Gross Profit | 7.68M |
| Operating Income | -128.99M |
| Net Income | -164.57M |
| EBITDA | -157.19M |
| EBIT | -128.99M |
| Earnings Per Share (EPS) | -5.81 |
Balance Sheet
The company has 139.53M in cash and 62.08M in debt, giving a net cash position of 77.45M.
| Cash & Cash Equivalents | 139.53M |
| Total Debt | 62.08M |
| Net Cash | 77.45M |
| Retained Earnings | -722.81M |
| Total Assets | 85.00M |
| Working Capital | 35.54M |
Cash Flow
In the last 12 months, operating cash flow was -109.71M and capital expenditures -272.00K, giving a free cash flow of -109.98M.
| Operating Cash Flow | -109.71M |
| Capital Expenditures | -272.00K |
| Free Cash Flow | -109.98M |
| FCF Per Share | -3.88 |
Margins
Gross margin is 7.73K%, with operating and profit margins of -129.82K% and -165.63K%.
| Gross Margin | 7.73K% |
| Operating Margin | -129.82K% |
| Pretax Margin | -165.63K% |
| Profit Margin | -165.63K% |
| EBITDA Margin | -1.58K% |
| EBIT Margin | -1.30K% |
| FCF Margin | -1.11K% |
Dividends & Yields
SYRS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -2420.83% |
| FCF Yield | -1686.72% |
Analyst Forecast
The average price target for SYRS is $3, which is 1150% higher than the current price. The consensus rating is "Hold".
| Price Target | $3 |
| Price Target Difference | 1150% |
| Analyst Consensus | Hold |
| Analyst Count | 5 |
Stock Splits
The last stock split was on Sep 19, 2022. It was a backward split with a ratio of 1:10.
| Last Split Date | Sep 19, 2022 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | -15.51 |
| Piotroski F-Score | 0 |